J Allergy Clin Immunol Pract:Dupilumab可改善中重度特应性皮炎成人的哮喘和鼻窦炎疗效

2021-02-09 AlexYang MedSci原创

在中重度特应性皮炎(AD)患者的临床试验中,Dupilumab具有疗效,且安全性可接受。最近,有研究人员在4项随机、双盲、安慰剂对照试验中评估了Dupilumab对中度至重度AD成年患者哮喘和鼻窦状况

在中重度特应性皮炎(AD)患者的临床试验中,Dupilumab具有疗效,且安全性可接受。最近,有研究人员在4项随机、双盲、安慰剂对照试验中评估了Dupilumab对中度至重度AD成年患者哮喘和鼻窦状况的影响

研究共包括了2444名患者,其中463名(19%)有哮喘,基线哮喘控制调查问卷-5(ACQ-5)≥0.5;1171名(48%)有鼻窦疾病;311名(13%)两者都有。在第16周的安慰剂、q2w(每两周300mg的Dupilumab剂量)和qw-(每周300mg的Dupilumab剂量)治疗的哮喘患者中,ACQ-5评分分别提高了(与基线相比的最小二乘平均变化[标准误差])0.27(0.07)、0.59(0.08)和0.56(0. 07);而在鼻窦疾病患者中SNOT-22评分分别提高了5.1(0.8)、9.9(0.9)和10.8(0.8)(所有P<0.01)。ACQ-5和SNOT-22的改善也出现在这两种情况具有的患者中。另外,在所有亚组中,Dupilumab也能显著改善AD症状和体征。

最后,研究人员指出,Dupilumab改善了中重度AD、哮喘和/或鼻窦疾病以,且具有临床意义和统计学意义(与安慰剂相比)

原始出处:

Mark Boguniewicz, Lisa A Beck, Lawrence Sher et al. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. Jan 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912537, encodeId=cfc1191253e94, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Mar 08 14:17:47 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282910, encodeId=3dc0128291032, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329464, encodeId=1c4913294645f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032793, encodeId=5e711032e937a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Feb 09 13:17:47 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-03-08 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912537, encodeId=cfc1191253e94, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Mar 08 14:17:47 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282910, encodeId=3dc0128291032, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329464, encodeId=1c4913294645f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032793, encodeId=5e711032e937a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Feb 09 13:17:47 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-02-11 zhyy88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912537, encodeId=cfc1191253e94, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Mar 08 14:17:47 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282910, encodeId=3dc0128291032, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329464, encodeId=1c4913294645f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032793, encodeId=5e711032e937a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Feb 09 13:17:47 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-02-11 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912537, encodeId=cfc1191253e94, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Mar 08 14:17:47 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282910, encodeId=3dc0128291032, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329464, encodeId=1c4913294645f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Feb 11 01:17:47 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032793, encodeId=5e711032e937a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Feb 09 13:17:47 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-02-09 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

J Asthma Allergy:手术在治疗鼻塞和控制哮喘中的作用

大多数哮喘患者,无论是过敏性或非过敏性的,通常都会表现出某种水平的并发鼻炎。鼻炎和哮喘的治疗均会对两种疾病产生影响。

Mol Med Rep:circARRDC3促进白细胞介素-13诱导的鼻腔上皮细胞炎症细胞因子和粘液的产生

过敏性鼻炎(AR)是一种常见的鼻黏膜炎症。它是哮喘发病的主要风险因素,且AR控制不佳可导致哮喘症状加重,影响患者的生活质量和生产效率。

Respir Med:当前哮喘、鼻炎、湿疹三联症在成年人中并不常见

之前已有研究人员在儿童中研究了哮喘、鼻炎和湿疹的共存情况,但在成人中缺乏数据。随着新的治疗方法的出现,需要对共存的流行病学数据进行研究。最近, 有研究人员调查了普通成人人群及对空气过敏原过敏者中哮喘、

World Allergy Organ J:MP-AzeFlu对过敏性鼻炎和哮喘患者的哮喘治疗实际效果评估

MP-AzeFlu(Dymista®;阿扎司汀/丙酸氟替卡松喷雾剂)是目前最有效的过敏性鼻炎(AR)治疗方法,但其对AR和哮喘患者哮喘的影响尚不清楚。

Eur Arch Otorhinolaryngol:哮喘和鼻炎患者中鼻腔通畅度与口面肌功能变化的关系

最近,有研究人员确定了口面肌功能变化与鼻腔通畅性的关系。

J Allergy Clin Immunol Pract:根诊断时的年龄和性别对哮喘缓解情况的影响

儿童发病的哮喘有很高的缓解概率,但成人发病的哮喘似乎较少缓解。关于缓解与哮喘发病年龄至成年晚期之间的关系的报道很少。最近,有研究人员评估了哮喘的缓解与哮喘发病年龄之间的关系,并评估不缓解的风险因素。